Neuronetics Stock Price, News & Analysis

MALVERN, Pa., Jan. 18, 2023 – Neuronetics, Inc. (NASDAQ: STIM) has announced the granting of inducement awards to three new non-executive employees as part of their hiring process. These awards, totaling 11,344 Restricted Stock Units (RSUs), have a fair value based on the closing stock price on the Nasdaq Global Select Market. The RSUs will vest in equal installments over three years, contingent on continued employment. Neuronetics, recognized as a leader in neuroscience, aims to enhance mental health treatment with its NeuroStar® Advanced Therapy system, which is FDA-cleared for major depressive disorder and other conditions.

Neuronetics, a medical technology company listed on NASDAQ under the ticker STIM, has settled its litigation against BrainsWay concerning unfair competition allegations. The settlement mandates BrainsWay to cease using specific efficacy data related to the treatment of anxious depression with NeuroStar Advanced Therapy. CEO Keith J. Sullivan reaffirmed the company's commitment to defending its data and the efficacy of NeuroStar. This therapy is FDA-cleared for major depressive disorder and has delivered over 5 million treatments, backed by extensive clinical data.

Neuronetics, Inc. (NASDAQ: STIM) reported preliminary unaudited revenue results for Q4 and full year 2022. Q4 revenue is approximately $18.0 million, exceeding guidance of $16.0 to $17.0 million. NeuroStar Advanced Therapy revenue for Q4 is projected at $4.6 million, while U.S. Treatment Session revenue is about $12.4 million. Full year 2022 revenue is expected to be $65.0 million, surpassing guidance of $63.0 to $64.0 million. The company attributes growth to successful marketing and education efforts, aiming for continued momentum in 2023.

Neuronetics, Inc. announces the appointment of Joseph H. Capper to its Board of Directors, effective January 1, 2023. Capper, with nearly 30 years of experience in med-tech, previously led BioTelemetry, Inc. and CCS Medical Inc. His expertise is expected to enhance Neuronetics' strategic goals, especially in addressing the growing mental health crisis post-pandemic. Capper's addition aims to strengthen the company's commitment to transforming neurohealth therapies, including the NeuroStar Advanced Therapy, which has delivered over 5 million treatments.

Neuronetics, Inc. (NASDAQ: STIM) announced the grant of 32,258 Restricted Stock Units (RSUs) to Rusty Page, VP Operations, as an inducement for his new role. This award, valued based on the December 1, 2022, closing stock price, will vest over three years subject to continued service. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, which is FDA-cleared for major depressive disorder and other conditions. The company emphasizes its commitment to transforming lives through innovative treatments backed by extensive clinical data.

Neuronetics (NASDAQ: STIM) has been recognized as a 2022 bronze winner by the Merit Awards in the HealthTech Patient Care category for its NeuroStar Advanced Therapy. The award highlights the company's commitment to enhancing patient care for those suffering from neurohealth disorders. With over 5 million treatments delivered, NeuroStar stands out as a leader in transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) and other psychiatric conditions. This accolade underscores Neuronetics' ongoing collaboration with the FDA to expand treatment indications.

Neuronetics, a medical technology company listed on NASDAQ as STIM, announced the granting of 69,758 Restricted Stock Units (RSUs) to ten new non-executive employees as part of their inducement to join the company. The RSUs vest in three equal installments over three years, contingent on continued employment. This move follows NASDAQ Listing Rule 5635(c)(4) and aims to enhance talent retention and attract skilled professionals in their field. Neuronetics focuses on neurohealth technologies, notably the NeuroStar system for treating mental health disorders.

Neuronetics, Inc. (NASDAQ: STIM) reported a 20% increase in Q3 2022 revenue, totaling $16.5 million, compared to $13.8 million in Q3 2021. The U.S. treatment session revenue reached a record $11.9 million, with a 51% rise in NeuroStar System revenue. The company raised its full-year revenue guidance to $63-64 million. Positive regulatory updates include FDA clearance for the D-Tect™ MT Accessory, and multiple TMS coverage policies improving patient access. However, operating expenses increased by 14.6% to $20.4 million, with a net loss of $(7.6) million, slightly better than the previous year.

Neuronetics, Inc. (NASDAQ: STIM) has been awarded the 2022 bronze medal in the HealthTech category by the Merit Awards for its NeuroStar Advanced Therapy, a notable innovation in mental health treatment.

NeuroStar offers a non-drug solution for psychiatric disorders, particularly depression. Over 4.8 million treatments have been delivered, supported by extensive clinical data. CEO Keith J. Sullivan emphasized the company's commitment to improving patient lives and continuing innovation in neurohealth.